Check-Cap Ltd. with ticker code (CHEK) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 2 and 1.5 calculating the average target price we see 1.75. Now with the previous closing price of 1.64 this would indicate that there is a potential upside of 6.7%. The 50 day MA is 0.63 and the 200 day moving average is 0.48. The market cap for the company is $73m. Visit the company website at: http://www.check-cap.com
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient’s back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon’s inner surface. The company was founded in 2004 and is based in Isfiya, Israel.